CD8A and cancer: However, aNSCLC did not seem to act as a driver of T senescence itself because the proportions of CD8+ senescent T cells in CMV− patients with IIIB-IV stages were similar to those of healthy volunteers, suggesting that even in the presence of cancer, CMV remains a mandatory driver of T cell senescence.